Trial Profile
Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Glimepiride; Insulin suspension isophane
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LANCELOT
- Sponsors Sanofi
- 20 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2011 Planned end date changed from 1 Jun 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.